|
|
| Overview: Type 2 diabetes mellitus (T2DM) accounts for approximately 90% to 95% of diabetes cases and is challenging to manage, with contributing pathophysiologic abnormalities ranging from predominant insulin resistance with relative insulin deficiency to predominant insulin secretory defect with insulin resistance. The leading cause of death in people with T2DM is cardiovascular disease (CVD), and patients with T2DM are at an increased risk of multiple cardiovascular comorbidities, such as heart failure and stroke. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a class of glucose-lowering medications capable of reducing cardiovascular risk while also helping patients achieve individualized glycemic goals; however, many clinicians remain unaware of both emerging cardiovascular and renal risk reduction data with these agents and recommendations for appropriate use of these agents in clinical practice. |
| Join our expert faculty as he provides the most up-to-date science regarding GLP-1 RAs. This engaging three-part webinar series focuses on current and emerging agents and evolving clinical guideline recommendations. Learn about currently available agents,their associated cardiovascular and renal benefits, novel formulations in late-stage development, important considerations for individualized patient care, and counseling and education strategies with the ultimate goal of improving care and outcomes in your patients with T2DM. |
| Provided in this webcast will be a downloadable Point-of-Care Reference Tool. This unique reference will serve as a valuable resource for your practice providing detailed information, at your fingertips, regarding the management of T2DM with GLP-1 RAs, efficacy of available agents, cardiovascular outcome considerations, and other relevant information as decided by the expert faculty. The Point-of-Care Reference Tool will be available as a downloadable pdf and will be optimized for mobile use at the point of care, as well, making it easy to access and share with colleagues. |
| Don't miss the final live webinar of this three-part webinar series |
|
| Thursday, January 16, 2020 at 1:00PM EST |
| Faculty Joshua J. Neumiller, PharmD, CDE, FAADE, FASCP |
| Vice-Chair & Allen I. White Distinguished Associate Professor of Pharmacotherapy Department of Pharmacotherapy College of Pharmacy and Pharmaceutical Sciences Washington State University Spokane, WA |
| Educational Objectives | ||||||||||||
|
||||||||||||
| UAN: 0430-0000-20-001-L01-P Credits: 1.25 hour (0.125 ceu) Activity Type: Application Duration: 75 minutes Location: From the convenience of your home or business; accessible via both PC and MAC Fee: There is no fee for this educational activity | ||||||||||||
| Missed part of this program? You may access the first two webinars in the series at powerpak.com |
||||||||||||
|
||||||||||||
| Required Computer Hardware/Software | ||||||||||||
|
||||||||||||
|
